[ad_1] MELBOURNE, Australia, Nov. 26, 2025 /PRNewswire/ — Neurizon® Therapeutics Limited (ASX: NUZ & NUZOA; OTCQB: NUZTF) (“Neurizon” or “the Company”), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to […]
Tag: Neurizon Therapeutics Limited
Elanco executive appointed as Neurizon’s Board Observer
[ad_1] MELBOURNE, Australia, Nov. 26, 2025 /PRNewswire/ — Neurizon® Therapeutics Limited (ASX: NUZ & NUZOA; OTCQB: NUZTF) (“Neurizon” or “the Company”), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to […]
Neurizon’s NUZ-001 Reduces Aggregation of Key ALS Disease Target TDP-43 in Preclinical Study
[ad_1] Highlights: Positive preclinical results in human in vitro iPSC Motor Neuron models of Amyotrophic Lateral Sclerosis (ALS) Neurizon’s lead drug NUZ-001 and its major active metabolite significantly and dose-dependently prevented the aggregation of TAR […]
Neurizon Therapeutics Receives Positive Opinion on Orphan Medicinal Product Designation for NUZ-001 in Europe
[ad_1] Highlights: Notice of positive opinion received from the European Medicines Agency for Orphan Medicinal Product Designation for NUZ-001 in Amyotrophic Lateral Sclerosis Orphan Designation offers 10 years of market exclusivity in Europe upon product approval, […]
